# Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer

> **NCT06639672** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Lei Liu** · enrollment: 60 (estimated)

## Conditions studied

- HR+HER2- Breast Cancer

## Interventions

- **DRUG:** Chemotherapy+PD-1 inhibitor+8Gy x 3f
- **DRUG:** Chemotherapy+PD-1 inhibitor+16Gy x 1f
- **DRUG:** Chemotherapy+PD-1 inhibitor+2.67Gy x 15f
- **DRUG:** Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f

## Key facts

- **NCT ID:** NCT06639672
- **Lead sponsor:** Lei Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2026-05-01
- **Final completion:** 2031-05-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06639672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06639672, "Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06639672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*